
In a groundbreaking study, international researchers enrolled 100 infants with new-onset epilepsy to assess the potential of rapid genome sequencing in diagnosis and treatment. They identified genetic causes in 43% of cases, with a median time of 37 days from seizure onset to diagnosis. Notably, genetic diagnosis influenced treatment, evaluation, prognosis, and recurrence risk counseling. The study highlights the feasibility and clinical utility of rapid genome sequencing in managing infantile epilepsy. Long-term follow-up will explore its impact on clinical outcomes.
Like
Save
Share